These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27212241)

  • 1. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.
    Belli LS; Berenguer M; Cortesi PA; Strazzabosco M; Rockenschaub SR; Martini S; Morelli C; Donato F; Volpes R; Pageaux GP; Coilly A; Fagiuoli S; Amaddeo G; Perricone G; Vinaixa C; Berlakovich G; Facchetti R; Polak W; Muiesan P; Duvoux C;
    J Hepatol; 2016 Sep; 65(3):524-31. PubMed ID: 27212241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.
    Perricone G; Duvoux C; Berenguer M; Cortesi PA; Vinaixa C; Facchetti R; Mazzarelli C; Rockenschaub SR; Martini S; Morelli C; Monico S; Volpes R; Pageaux GP; Fagiuoli S; Belli LS;
    Liver Int; 2018 Dec; 38(12):2170-2177. PubMed ID: 29750389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    Pascasio JM; Vinaixa C; Ferrer MT; Colmenero J; Rubin A; Castells L; Manzano ML; Lorente S; Testillano M; Xiol X; Molina E; González-Diéguez L; Otón E; Pascual S; Santos B; Herrero JI; Salcedo M; Montero JL; Sánchez-Antolín G; Narváez I; Nogueras F; Giráldez Á; Prieto M; Forns X; Londoño MC
    J Hepatol; 2017 Dec; 67(6):1168-1176. PubMed ID: 28842296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    Pose E; Torrents A; Reverter E; Perez-Campuzano V; Campos-Varela I; Avitabile E; Gratacós-Ginès J; Castellote J; Castells L; Colmenero J; Tort J; Ginès P; Crespo G
    J Hepatol; 2021 Aug; 75(2):275-283. PubMed ID: 33746085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
    Meunier L; Belkacemi M; Pageaux GP; Radenne S; Vallet-Pichard A; Houssel-Debry P; Duvoux C; Botta-Fridlund D; de Ledinghen V; Conti F; Anty R; Di Martino V; Debette-Gratien M; Leroy V; Gerster T; Lebray P; Alric L; Abergel A; Dumortier J; Besch C; Montialoux H; Samuel D; Duclos-Vallée JC; Coilly A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience.
    Nabatchikova EA; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Moiseev SV
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101714. PubMed ID: 33930587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.
    Daniel KE; Said A
    Curr Gastroenterol Rep; 2018 Apr; 20(5):20. PubMed ID: 29623506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent.
    Bittermann T; Reddy KR
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2389-2397.e2. PubMed ID: 32971230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C Virus Positive Patients on the Waiting List for Liver Transplantation: Turnover and Characteristics of the Population on the Eve of the Therapeutic Revolution With Direct-Acting Antivirals.
    Trapani S; Rizzato L; Masiero L; Ricci A; Morabito V; Peritore D; Fiaschetti P; Del Sordo E; Cacciotti AR; Montemurro A; Nanni Costa A
    Transplant Proc; 2017 May; 49(4):658-666. PubMed ID: 28457366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease.
    Reddy KR; O'Leary JG; Kamath PS; Fallon MB; Biggins SW; Wong F; Patton HM; Garcia-Tsao G; Subramanian RM; Thacker LR; Bajaj JS;
    Liver Transpl; 2015 Jul; 21(7):881-8. PubMed ID: 25845966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
    Sandmann L; Dörge P; Wranke A; Vermehren J; Welzel TM; Berg CP; Grottenthaler JM; Weiss KH; Langel J; Sterneck M; von Wulffen M; Manns MP; Wedemeyer H; Hardtke S; von Hahn T
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1049-1056. PubMed ID: 30807443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
    Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
    J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
    Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.
    Cortesi PA; Belli LS; Facchetti R; Mazzarelli C; Perricone G; De Nicola S; Cesana G; Duvoux C; Mantovani LG; Strazzabosco M;
    J Viral Hepat; 2018 Jul; 25(7):791-801. PubMed ID: 29406608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation for hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study.
    Khan AS; Adams N; Vachharajani N; Dageforde L; Wellen J; Shenoy S; Crippin JS; Doyle MB; Chapman WC
    Int J Surg; 2020 Mar; 75():84-90. PubMed ID: 32014598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.